Lipoprotein(a) and thrombocytes: Potential mechanisms underlying cardiovascular risk

William Discepolo, Theodore Wun, Lars Berglund

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Plasma levels of lipoprotein(a), Lp(a), is an independent risk factor for cardiovascular disease. Lp(a) has many properties in common with low-density lipoprotein (LDL), including a cholesteryl ester-rich lipid core and the presence of one copy of apolipoprotein B-100; both apoB-100 and the lipid core are pro-atherogenic. In addition, Lp(a) contains a unique hydrophilic, carbohydrate-rich protein, apo(a), linked to apoB through a single disulfide bond connecting the C-terminal regions of the two proteins. The similarities between apolipoprotein(a), apo(a), and plasminogen has initiated numerous studies on the possible role of Lp(a) as a pro-thrombotic agent. Studies to date suggest that Lp(a) has antifibrinolytic and procoagulant properties. In this review, we summarize recent studies focused on the interaction between Lp(a) and platelets. Collectively, results to date illustrate that thrombogenicity associated with Lp(a) could be due to risk associated with the LDL moiety, with the apo(a) moiety, or from the combination of those in Lp(a). Present findings suggest that the various components of Lp(a) may impact to a varying degree on different underlying pathways involved in platelet activation and aggregation. On balance, results indicate an effect by Lp(a) on platelet function and future studies focused on specific Lp(a) components, such as the role of apo(a) and of the LDL-like lipid moiety, are needed.

Original languageEnglish (US)
Pages (from-to)314-321
Number of pages8
JournalPathophysiology of Haemostasis and Thrombosis
Volume35
Issue number3-4
DOIs
StatePublished - Jul 2006

Fingerprint

Lipoprotein(a)
LDL Lipoproteins
Apolipoprotein B-100
Blood Platelets
Lipids
Apoprotein(a)
Antifibrinolytic Agents
Cholesterol Esters
Plasminogen
Platelet Activation
Apolipoproteins B
Platelet Aggregation
Disulfides
Proteins
Cardiovascular Diseases
Carbohydrates

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • Fibrinolysis
  • Lipoprotein(a)
  • Thrombocytes
  • Thrombosis

ASJC Scopus subject areas

  • Hematology

Cite this

Lipoprotein(a) and thrombocytes : Potential mechanisms underlying cardiovascular risk. / Discepolo, William; Wun, Theodore; Berglund, Lars.

In: Pathophysiology of Haemostasis and Thrombosis, Vol. 35, No. 3-4, 07.2006, p. 314-321.

Research output: Contribution to journalArticle

@article{47409d19499e421fb3fda556ac1f2296,
title = "Lipoprotein(a) and thrombocytes: Potential mechanisms underlying cardiovascular risk",
abstract = "Plasma levels of lipoprotein(a), Lp(a), is an independent risk factor for cardiovascular disease. Lp(a) has many properties in common with low-density lipoprotein (LDL), including a cholesteryl ester-rich lipid core and the presence of one copy of apolipoprotein B-100; both apoB-100 and the lipid core are pro-atherogenic. In addition, Lp(a) contains a unique hydrophilic, carbohydrate-rich protein, apo(a), linked to apoB through a single disulfide bond connecting the C-terminal regions of the two proteins. The similarities between apolipoprotein(a), apo(a), and plasminogen has initiated numerous studies on the possible role of Lp(a) as a pro-thrombotic agent. Studies to date suggest that Lp(a) has antifibrinolytic and procoagulant properties. In this review, we summarize recent studies focused on the interaction between Lp(a) and platelets. Collectively, results to date illustrate that thrombogenicity associated with Lp(a) could be due to risk associated with the LDL moiety, with the apo(a) moiety, or from the combination of those in Lp(a). Present findings suggest that the various components of Lp(a) may impact to a varying degree on different underlying pathways involved in platelet activation and aggregation. On balance, results indicate an effect by Lp(a) on platelet function and future studies focused on specific Lp(a) components, such as the role of apo(a) and of the LDL-like lipid moiety, are needed.",
keywords = "Atherosclerosis, Cardiovascular disease, Fibrinolysis, Lipoprotein(a), Thrombocytes, Thrombosis",
author = "William Discepolo and Theodore Wun and Lars Berglund",
year = "2006",
month = "7",
doi = "10.1159/000093224",
language = "English (US)",
volume = "35",
pages = "314--321",
journal = "Pathophysiology of Haemostasis and Thrombosis",
issn = "1424-8832",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Lipoprotein(a) and thrombocytes

T2 - Potential mechanisms underlying cardiovascular risk

AU - Discepolo, William

AU - Wun, Theodore

AU - Berglund, Lars

PY - 2006/7

Y1 - 2006/7

N2 - Plasma levels of lipoprotein(a), Lp(a), is an independent risk factor for cardiovascular disease. Lp(a) has many properties in common with low-density lipoprotein (LDL), including a cholesteryl ester-rich lipid core and the presence of one copy of apolipoprotein B-100; both apoB-100 and the lipid core are pro-atherogenic. In addition, Lp(a) contains a unique hydrophilic, carbohydrate-rich protein, apo(a), linked to apoB through a single disulfide bond connecting the C-terminal regions of the two proteins. The similarities between apolipoprotein(a), apo(a), and plasminogen has initiated numerous studies on the possible role of Lp(a) as a pro-thrombotic agent. Studies to date suggest that Lp(a) has antifibrinolytic and procoagulant properties. In this review, we summarize recent studies focused on the interaction between Lp(a) and platelets. Collectively, results to date illustrate that thrombogenicity associated with Lp(a) could be due to risk associated with the LDL moiety, with the apo(a) moiety, or from the combination of those in Lp(a). Present findings suggest that the various components of Lp(a) may impact to a varying degree on different underlying pathways involved in platelet activation and aggregation. On balance, results indicate an effect by Lp(a) on platelet function and future studies focused on specific Lp(a) components, such as the role of apo(a) and of the LDL-like lipid moiety, are needed.

AB - Plasma levels of lipoprotein(a), Lp(a), is an independent risk factor for cardiovascular disease. Lp(a) has many properties in common with low-density lipoprotein (LDL), including a cholesteryl ester-rich lipid core and the presence of one copy of apolipoprotein B-100; both apoB-100 and the lipid core are pro-atherogenic. In addition, Lp(a) contains a unique hydrophilic, carbohydrate-rich protein, apo(a), linked to apoB through a single disulfide bond connecting the C-terminal regions of the two proteins. The similarities between apolipoprotein(a), apo(a), and plasminogen has initiated numerous studies on the possible role of Lp(a) as a pro-thrombotic agent. Studies to date suggest that Lp(a) has antifibrinolytic and procoagulant properties. In this review, we summarize recent studies focused on the interaction between Lp(a) and platelets. Collectively, results to date illustrate that thrombogenicity associated with Lp(a) could be due to risk associated with the LDL moiety, with the apo(a) moiety, or from the combination of those in Lp(a). Present findings suggest that the various components of Lp(a) may impact to a varying degree on different underlying pathways involved in platelet activation and aggregation. On balance, results indicate an effect by Lp(a) on platelet function and future studies focused on specific Lp(a) components, such as the role of apo(a) and of the LDL-like lipid moiety, are needed.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Fibrinolysis

KW - Lipoprotein(a)

KW - Thrombocytes

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33746627292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746627292&partnerID=8YFLogxK

U2 - 10.1159/000093224

DO - 10.1159/000093224

M3 - Article

C2 - 16877880

AN - SCOPUS:33746627292

VL - 35

SP - 314

EP - 321

JO - Pathophysiology of Haemostasis and Thrombosis

JF - Pathophysiology of Haemostasis and Thrombosis

SN - 1424-8832

IS - 3-4

ER -